10-Q: QT Imaging Holdings Reports Q3 Revenue Surge, Secures $18M Capital

QT Imaging Holdings, Inc. reported a significant 339% increase in Q3 2025 revenue, driven by increased scanner sales and new distribution agreements, while also securing $18.18 million in a private placement post-quarter.

Summary

• Revenue for the three months ended September 30, 2025, increased by 339% to $4,192,101, compared to $955,970 for the same period in 2024.
• Revenue for the nine months ended September 30, 2025, increased by 164% to $10,649,930, compared to $4,032,168 for the same period in 2024.
• Net loss for the three months ended September 30, 2025, was $4,557,406, compared to a net loss of $3,619,494 for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $19,694,921, compared to a net loss of $5,496,958 for the same period in 2024.
• The company sold 9 QT Breast Scanners in Q3 2025, an increase from 2 scanners sold in Q3 2024.
• The company sold 23 QT Breast Scanners in the first nine months of 2025, up from 9 scanners in the first nine months of 2024.
• An accumulated deficit of $51,635,448 was reported as of September 30, 2025.
• Post-quarter, the company secured aggregate gross proceeds of $18,180,655 from an October 2025 Private Placement.
• A 3:1 reverse stock split became effective on October 23, 2025, and the company has applied to relist on the Nasdaq Capital Market.
• A new exclusive distribution agreement was signed with Gulf Medical Co. for Saudi Arabia, with minimum order quantities (MOQs) projected at $11.2 million to $12.3 million in 2026.

Sentiment

Score: 5

Explanation: While the company achieved significant revenue growth and successfully raised substantial capital, the net loss for the nine-month period dramatically increased, driven by non-cash expenses related to financing activities. The accumulated deficit remains high, and the company continues to be cash flow negative from operations, indicating ongoing financial challenges despite operational progress and strategic partnerships. The reverse stock split also adds a layer of concern.

Positives

• Significant revenue growth: 339% increase in Q3 2025 revenue to $4,192,101 and 164% increase in nine-month 2025 revenue to $10,649,930, driven by increased QT Breast Scanner sales.
• Successful capital raise: Secured $18,180,655 in gross proceeds from the October 2025 Private Placement, providing crucial working capital.
• Debt management: Repaid the $5.0 million Tranche B of the Lynrock Lake Term Loan on October 6, 2025, reducing debt obligations.
• Expanded distribution: Entered into an exclusive distribution agreement with Gulf Medical Co. for Saudi Arabia, with MOQs of $11.2 million to $12.3 million in 2026, indicating international market expansion.
• Manufacturing scalability: The Canon Manufacturing Agreement provides the ability to scale manufacturing with favorable net 90-day payment terms, supporting increased demand.
• Improved liquidity outlook: Management believes current cash and anticipated revenues will fund operations for at least the next 12 months.
• Reduced operating loss: Loss from operations decreased by 29% in Q3 2025 to $(1,652,079) compared to $(2,327,188) in Q3 2024.

Negatives

• Increased net loss: Net loss for the nine months ended September 30, 2025, significantly increased to $19,694,921 from $5,496,958 in the prior year, primarily due to non-cash expenses related to financing activities.
• Accumulated deficit: The company has an accumulated deficit of $51,635,448 as of September 30, 2025, indicating a history of unprofitability.
• Negative cash flow from operations: Used $5,857,572 of cash in operating activities for the nine months ended September 30, 2025.
• Dilution risk: Future equity issuances for capital raising could lead to significant dilution for existing stockholders.
• Warrant liability impact: Changes in fair value of warrant liability resulted in an $80,043 expense in Q3 2025 and a $3,581,122 expense for the nine months ended September 30, 2025.
• Earnout liability increase: Change in fair value of earnout liability resulted in a $2,230,000 expense in Q3 2025 and a $2,070,000 expense for the nine months ended September 30, 2025, driven by increased revenue assumptions.
• High customer concentration: Customer A (NXC Imaging) accounted for 99% of revenue in Q3 2025 and 99% for the nine months ended September 30, 2025, posing a significant business risk.
• Supply chain risk: Dependence on a limited number of suppliers for critical components of the QT Breast Scanner.
• Reverse stock split: The 3:1 reverse stock split, while a technical adjustment, can be perceived negatively by the market, often associated with low stock prices and efforts to meet listing requirements.

Risks

• Being a development-stage company with limited operating history and significant losses, making it difficult to evaluate future viability and predict performance.
• Ability to successfully execute the business model, including market acceptance of planned products and product candidates at acceptable prices.
• Ability to have products accepted by hospitals, clinics, and medical professionals, and to have a sufficient number of trained radiologists to review images.
• Ability to repay debt cash obligations as they come due.
• The occurrence of a pandemic, epidemic, or outbreak of infectious disease that may materially or adversely affect business, financials, and product development.
• Ability to raise additional capital on acceptable terms or at all.
• The effect of debt agreements on the company's flexibility in operating the business.
• Ability to sustain revenue growth or profitability.
• Risks associated with doing business globally, including tariffs or other restrictions related to trade wars.
• Risk of incurring uninsured losses.
• Ability to maintain the confidentiality and integrity of the company's data and other sensitive information.
• Ability of the business to respond to changes in general economic conditions.
• The occurrence of technological changes.
• Success in recruiting and retaining key employees.
• Ability to manage growth effectively.
• Ability to compete and adapt in the medical imaging industry.
• The outcome of any legal proceedings that may be instituted against the business and other litigation and regulatory risks.
• Ability to obtain additional clearances and approvals from the FDA for current and future products.
• The effect of unanticipated changes in effective tax rates on operations and financials.
• Ability to adequately protect the company's intellectual property rights.
• The impact of the terms and conditions of licenses and sublicenses granted by third-parties.
• Management team's limited experience managing a public company.
• Officers and directors allocating their time to other businesses and potentially having conflicts of interest with the company's business.
• The effect of the issuance of additional shares of common stock on the stock price.
• Future sales, or perception of future sales, of common stock by the company or existing stockholders in the public market could cause the market price to decline.
• The company's governing documents' effect on stock price and stockholders' ability to gain favorable judicial forums.
• The effect of the company's warrants on the market price of the common stock.
• Ability to enforce covenants not to compete.
• The uncertainty of industry data, projections, and estimates.
• The effect of write-downs and write-offs that the company may be required to take.
• Ability to maintain internal controls over financial reports.

Future Outlook

Management believes that the additional cash received from the Lynrock Lake Term Loan, PIPE investments closed in April, May, and October 2025, and the additional expected revenue from minimum order quantities (MOQs) per the Amended Distribution Agreement and the Gulf Medical Distribution Agreement will be sufficient to fund the current operating plan for at least the next 12 months. The company expects to continue incurring losses and negative cash flows from operations in the foreseeable future, with profitability dependent on achieving sufficient revenues. Research and development expenses are anticipated to increase substantially as the company invests in QT Breast Scanner development, a Cloud SaaS platform, clinical trials, and cost reduction. Selling, general, and administrative expenses are also expected to rise to support expanding headcount, public company costs, commercial infrastructure, and distribution partnerships. The company plans to raise future capital through equity, borrowings, and potential strategic alliances.

Management Comments

• "Management believes that the additional cash received from the Lynrock Lake Term Loan, the PIPE investments closed in April, May, and October 2025, and the additional expected revenue from MOQs per the Amended Distribution Agreement and the Gulf Medical Distribution Agreement will be sufficient to fund the Companys current operating plan for at least the next 12 months."
• "The Company expects to continue to incur losses, and its ability to achieve and sustain profitability will depend on the achievement of sufficient revenues to support the Companys cost structure. The Company may never achieve profitability and, unless and until it does, the Company will need to continue to raise additional capital."
• "We believe that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, and accessible."
• "Our goal is to improve global health outcomes through the development and commercialization of imaging devices that address critical healthcare challenges with accuracy and precision."
• "Our use of the words safe, safety, effectiveness, and efficacy in relation to the QT Breast Scanner in this Management's Discussion and Analysis and all other documents related to us is limited to the context of the Section 510(K) Summary of Safety and Effectiveness that was reviewed and responded to by the FDA."
• "We expect our cost of revenue to increase in absolute dollars and decrease as a percentage of revenues over time as we shift to new manufacturing processes and vendors that we anticipate will result in greater efficiency and lower per unit costs."
• "We expect that our research and development expenses will increase substantially for the foreseeable future as we continue to invest in the development of the QT Breast Scanner."
• "We anticipate that our selling, general and administrative expenses will increase to support our expanding headcount and operations, increased costs of operating as a public company, the development of a commercial infrastructure to support commercialization of our products and product candidates, increased support for existing and new distribution partner relationships, and the use of outside service providers such as insurers, consultants, lawyers, and accountants."

Industry Context

QT Imaging Holdings operates in the highly competitive medical device industry, specializing in body imaging systems using low-frequency sound waves, with a primary focus on breast imaging. The company's strategy to leverage "disruptive technological innovation (software, artificial intelligence, and smart physics)" aligns with broader industry trends towards advanced diagnostics and patient-centric care. Strategic partnerships with distributors like NXC Imaging (U.S.) and Gulf Medical Co. (Saudi Arabia) are a common approach for medical device companies to expand market reach and scale operations. The development of a Cloud SaaS platform and the pursuit of biomarker data indicate an alignment with the growing digital health and precision medicine sectors.

Comparison to Industry Standards

• The QT Breast Scanner was determined by the FDA to be "substantially equivalent" to the predicate device, SoftVue System manufactured by Delphinus Medical Technologies, on June 6, 2017, serving as a regulatory benchmark for market entry.
• No other specific comparable companies, projects, or results are detailed for direct financial or operational comparison within the filing. The company's focus is on internal growth and strategic partnerships rather than benchmarking against specific competitors' performance metrics.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings, nor is any material legal proceeding threatened against the company or its officers/directors in their corporate capacity.

Related Party Transactions

• Convertible Notes Payable (2020 Notes): Issued in July 2020 (and March 2022) to three stockholders for advances up to $3,500,000, bearing 5% (or 8%) annual interest. Maturity extended to October 21, 2027. Outstanding amount $3,190,112 as of September 30, 2025.
• Working Capital Loan: Promissory note issued to a stockholder on May 3, 2023, for $250,000, subsequently amended multiple times to an aggregate principal of $705,000 as of September 30, 2025. Interest-free. Maturity extended to October 1, 2027.
• April 2025 Private Placement: On April 24, 2025, the company received $500,000 from Dr. Avi Katz (Chairman) and Dr. Raluca Dinu (CEO) in exchange for 261,644 shares of common stock and warrants to purchase 523,286 shares of common stock.

Stakeholder Impact

• Shareholders: Face potential significant dilution from future equity issuances and warrant exercises. The 3:1 reverse stock split impacts share count and price. Market price could be negatively affected by future sales by existing stockholders or warrant liability changes. Positive impact from revenue growth and new distribution agreements.
• Employees: Benefit from stock-based compensation plans and increased employee compensation expenses. Expanding headcount and operations indicate growth opportunities.
• Customers: Gain access to the QT Breast Scanner through expanded distribution channels (NXC in U.S., Gulf Medical Co. in Saudi Arabia). The company's focus on safety, affordability, and accessibility aims to benefit customers. Products come with a limited warranty.
• Suppliers/Creditors: Canon Manufacturing Agreement provides favorable payment terms (net 90 days). However, dependence on a limited number of suppliers for critical components poses a supply risk. The company has significant debt obligations (Lynrock Lake Term Loan, related party notes).

Next Steps

• Continue to invest in the development of the QT Breast Scanner.
• Build the Cloud SaaS platform.
• Run clinical trials to generate biomarker data.
• Reduce the bill of materials (BOM) and other manufacturing costs for the QT Breast Scanner.
• Expand and further develop product offerings.
• Expand marketing efforts to increase product adoption.
• Obtain regulatory approvals for product candidates and expanded regulatory clearances for the QT Breast Scanner.
• Build a U.S. sales and marketing team.
• Establish new licensing or collaboration arrangements outside of the U.S.
• Hire additional personnel to support growth.
• Prepare, file, and prosecute patent applications, and maintain/enforce intellectual property rights.
• Relist on the Nasdaq Capital Market (application submitted).

Key Dates

Recommendation

The company demonstrates strong revenue growth and has successfully secured significant capital, which are positive indicators for its operational expansion and liquidity. However, the substantial increase in net loss for the nine-month period, primarily due to non-cash financing-related expenses, and the ongoing accumulated deficit highlight significant financial challenges. The recent reverse stock split and potential for future dilution also introduce uncertainty. While strategic partnerships and product development show promise, the company remains in a development stage with unproven long-term profitability. A "Hold" recommendation is appropriate as investors should monitor the company's ability to translate revenue growth into sustainable profitability and manage its debt and equity structure effectively before making further investment decisions.

Keywords

QT Imaging Holdings, medical device, breast imaging, QT Breast Scanner, SEC filing, 10-Q, financial results, revenue growth, net loss, capital raise, private placement, distribution agreement, NXC Imaging, Gulf Medical Co., Lynrock Lake Term Loan, reverse stock split, corporate governance, risk factors, medical technology, diagnostic imaging, FDA clearance, Sio Capital Management